摘要
目的 探讨卡维地洛 (CAV)治疗心力衰竭的疗效及机制。方法 对慢性心衰病人 76例 ,随机分为 3组 :常规治疗组 2 0例 (A组 )、卡维地洛组 3 0例 (B组 )、美托洛尔组 2 6例 (C组 ) ,治疗前后分别观察心功能变化、测量LVEF、左室质量及血浆脂质过氧化物 (LPO)和超氧化物歧化酶 (SOD)的水平。结果 (1)B组和C组治疗 6个月后患者心功能明显好转 ,且疗效优于A组(P <0 0 1) ,但B组和C组之间疗效差异无显著性 (P >0 0 5 )。 (2 )B组血浆LPO水平较治疗前下降 ,红细胞SOD升高 (P <0 0 1) ,而A组和C组治疗前后无明显变化。结论 CAV对慢性心衰有明显治疗作用 。
AIM To investigate the effect of carvedilol on heart with cardiac dysfunction and its mechanism. METHODS Seventy six patients with congestive heart failure were randomly divided into three groups. The control group (A group, n =20)received medical therapy including digitalis, diuretics, vitamines and prepared CH. medicine. The carvedilol group (B group, n= 30),on the basic therapy above, carvedilol was administered. In the metoprolol group(C group, n =26), metoprolol was administered. Ventricular function, plasma lipid peroxide (LPO) and erythrocyte superoxide dismutase (SOD) activity were measured before and after therapy. RESULTS After six months, heart function has greatly improved in group B and C ( P <0 01), but there was no significant differences between the two groups ( P> 0 05). The effect of therapy in group B and group C is better than that in group A ( P <0 01). The level of LPO was significantly decreased, but SOD increased in group B. However, this phenomenon was not observed in group A and C. CONCLUSIONS CAV not only has effect of improving cardiac dysfunction, but has effect of anti lipid peroxide.
出处
《安徽医药》
CAS
2003年第2期100-102,共3页
Anhui Medical and Pharmaceutical Journal
关键词
卡维地洛
治疗
心力衰竭
美托洛尔
congestive heart
failure
carvedilol
lipid peroxide
superoxide dismutase
